Finzati - Logo
RVTY logo

Revvity, Inc.

RVTY • Medical - Diagnostics & Research
$130.22
▼ -0.41 (-0.31%)
Current price
EarningsLatest report: Jul 5, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$14.55B
Growth
2.1%
Cash Flow
5/5
Trend
Stable
Evidence
Positive free cash flow · 4.49Consistent free cash flow · 5/5Manageable debt level · 0.48Healthy liquidity · 1.68Expensive earnings multiple · 45.49
Financial data as of: Jul 5, 2026, 12:00 AM UTCLast earnings update: Jul 5, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:06 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$130.22
Change-0.31%
Shares Out111.75M
Market Cap$14.55B
Enterprise Value$16.87B
52W Range81.22 - 118.30
Beta1.07
P/E61.26
P/S5.00
P/B2.01
P/FCF26.01
EV/Sales5.79

Investment DNA

How strong this company looks for long-term investors

60
out of 100
Business Quality
Margins, moat, returns
52/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
60/100
Why this score▼
Positive free cash flow · 4.49Consistent free cash flow · 5/5Manageable debt level · 0.48Healthy liquidity · 1.68Expensive earnings multiple · 45.49Negative growth trend

Analyst view

Analyst sentiment and price target

RVTY
Analyst sentiment
Based on 29 analyst votes · 2026-09-05
76/100
Bullish
Bullish
15
Hold
14
Bearish
0
Price Target
2026-08-13
Low
$95.00
Mean
$110.40
Median
$115.00
High
$125.00

Company Overview

IPO: 7/6/1965
Industry: Medical - Diagnostics & Research
P/B i: 2.01
Debt / Equity i: 0.48
Operating Margin: 12.49%
Net Margin: 8.46%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.48
Current Ratio: 1.68
Quick Ratio: 1.40
Status: Good

Insider Transactions

Recent executive and insider activity

Gonzales Anita
Transaction: 07/20/2026
SELL
Change
-85
Price
$109.48
Filing
07/22/2026
Type
SELL
Gonzales Anita
Transaction: 06/15/2026
SELL
Change
-33
Price
$99.66
Filing
06/17/2026
Type
SELL
Witz Pascale
Transaction: 05/07/2026
BUY
Change
+1,015
Price
Not reported
Filing
05/11/2026
Type
BUY